ACTRIMS 2022

#ACTRIMS2022 ā€“ Blood NfL Levels May Help Quantify Relapse Severity

Measuring levels of the neurofilament light chain (NfL) protein in blood may be a way to “quantify” relapse severity and predict future disability in people with relapsing-remitting multiple sclerosis (RRMS). “Higher [blood] NfL levels during periods of active inflammation predicted more [brain] atrophy,” researchers wrote in an abstract titled…

#ACTRIMS2022 ā€“ Tolebrutinib More Potent Than Other BTK Blockers

Tolebrutinib, an investigative inhibitor of Brutonā€™s tyrosine kinase (BTK) being developed byĀ SanofiĀ to treat all forms ofĀ multiple sclerosis (MS), shows the potential to be more potent than other BTK inhibitors also in advanced clinical trials, scientists reported. The findings, based on preclinical data, were shared at the Americas…

#ACTRIMS2022 ā€“ Algorithm Predicts Relapse Risk Using EHR Data

Using a two-step machine learning strategy, researchers have developed an algorithm to predict the risk of multiple sclerosis (MS) relapse based on data gleaned from electronic health records. “The two-step machine learning model predicts a patient’s future one-year MS relapse risk with clinically actionable accuracy, comparable to other clinical…

#ACTRIMS2022 ā€“ In New Mouse Model, Evobrutinib Shows Efficacy

Researchers developed a new mouse model that more closely captures a specific type of inflammation characteristic of progressive multiple sclerosis (MS) ā€” and found, in experiments, that treatment with an oral medicationĀ called evobrutinibĀ can lessen disease activity. This new mouse model may help scientists in MS to better study…